ANAGENICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 AUD | +11.11% |
|
+11.11% | -47.37% |
| Mar. 08 | Anagenics Appoints CEO | MT |
| Feb. 26 | Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 26.75 | 14.63 | 12.07 | 11.25 | 5.083 | 6.216 |
| Enterprise Value (EV) 1 | 28.31 | 12.84 | 7.061 | 5.952 | 3.556 | 4.303 |
| P/E ratio | -6.97 x | -2.24 x | -1.98 x | -2.5 x | -1.32 x | -1.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.67 x | 1.96 x | 1.61 x | 1.93 x | 0.55 x | 0.68 x |
| EV / Revenue | 4.94 x | 1.72 x | 0.94 x | 1.02 x | 0.39 x | 0.47 x |
| EV / EBITDA | -9.08 x | -4.33 x | -1.62 x | -1.92 x | -1.07 x | -2.61 x |
| EV / FCF | -8.43 x | -5.43 x | -3.41 x | -1.93 x | -3.58 x | -19.2 x |
| FCF Yield | -11.9% | -18.4% | -29.3% | -51.7% | -27.9% | -5.2% |
| Price to Book | 14.4 x | 2.51 x | 1.28 x | 1.08 x | 0.61 x | 0.7 x |
| Nbr of stocks (in thousands) | 56,912 | 83,609 | 120,701 | 187,431 | 221,021 | 365,620 |
| Reference price 2 | 0.4700 | 0.1750 | 0.1000 | 0.0600 | 0.0230 | 0.0170 |
| Announcement Date | 9/19/18 | 8/28/19 | 8/27/20 | 9/19/21 | 8/24/22 | 9/14/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.727 | 7.462 | 7.482 | 5.816 | 9.235 | 9.113 |
| EBITDA 1 | -3.12 | -2.966 | -4.366 | -3.095 | -3.33 | -1.648 |
| EBIT 1 | -3.307 | -3.119 | -4.602 | -3.253 | -3.419 | -1.769 |
| Operating Margin | -57.76% | -41.8% | -61.51% | -55.93% | -37.03% | -19.41% |
| Earnings before Tax (EBT) 1 | -3.73 | -5.885 | -4.818 | -3.76 | -3.644 | -1.734 |
| Net income 1 | -3.733 | -5.91 | -4.907 | -3.387 | -3.649 | -2.667 |
| Net margin | -65.18% | -79.19% | -65.59% | -58.23% | -39.51% | -29.27% |
| EPS 2 | -0.0674 | -0.0780 | -0.0504 | -0.0240 | -0.0174 | -0.0100 |
| Free Cash Flow 1 | -3.36 | -2.365 | -2.069 | -3.076 | -0.9932 | -0.2238 |
| FCF margin | -58.68% | -31.69% | -27.65% | -52.89% | -10.76% | -2.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/19/18 | 8/28/19 | 8/27/20 | 9/19/21 | 8/24/22 | 9/14/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.57 | - | - | - | - | - |
| Net Cash position 1 | - | 1.8 | 5.01 | 5.29 | 1.53 | 1.91 |
| Leverage (Debt/EBITDA) | -0.502 x | - | - | - | - | - |
| Free Cash Flow 1 | -3.36 | -2.36 | -2.07 | -3.08 | -0.99 | -0.22 |
| ROE (net income / shareholders' equity) | -126% | -153% | -62.6% | -37.6% | -39% | -20.3% |
| ROA (Net income/ Total Assets) | -27.8% | -23.6% | -23.3% | -14.4% | -16.3% | -9.2% |
| Assets 1 | 13.45 | 25.07 | 21.05 | 23.47 | 22.38 | 29 |
| Book Value Per Share 2 | 0.0300 | 0.0700 | 0.0800 | 0.0600 | 0.0400 | 0.0200 |
| Cash Flow per Share 2 | 0.0300 | 0.0400 | 0.0600 | 0.0400 | 0.0100 | 0.0100 |
| Capex 1 | 0.11 | 0.07 | - | 0.02 | 0.04 | 0.05 |
| Capex / Sales | 1.87% | 0.88% | - | 0.39% | 0.39% | 0.5% |
| Announcement Date | 9/19/18 | 8/28/19 | 8/27/20 | 9/19/21 | 8/24/22 | 9/14/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -47.37% | 2.71M | |
| +10.32% | 381B | |
| +8.03% | 129B | |
| -16.39% | 62.59B | |
| +0.37% | 52.86B | |
| -11.47% | 36.11B | |
| +2.76% | 33.57B | |
| +9.68% | 17.29B | |
| +7.68% | 14.75B | |
| -9.06% | 10.82B |
- Stock Market
- Equities
- AN1 Stock
- Financials Anagenics Limited
